![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Catco Reinsurance Opportunities Fund Limited | LSE:CAT | London | Ordinary Share | BMG1961Q3242 | ORD USD0.00013716 (DI) |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 24.00 | 13.00 | 35.00 | 24.00 | 24.00 | 24.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Unit Inv Tr, Closed-end Mgmt | 6.33M | 5.44M | 3.6440 | 6.59 | 35.84M |
RNS No 2772t CAMBRIDGE ANTIBODY TECHNOLOGY GROUP PLC 27 April 1999 For Further Information Contact: Cambridge Antibody Technology Group plc Dr David Chiswell, Chief Executive Officer Tel: +44 (0) 1763 263233 John Aston, Finance Director HCC.De Facto City/Financial, Nicola How Scientific/Trade, Andrew Worsfold Tel: +44 (0) 171 496 3300 US Patent Melbourn, UK - Cambridge Antibody Technology holds a granted US patent with broad claims directed to human antibodies to human proteins isolated by phage display and to methods for producing human antibodies (US 5,885,793). This patent was granted on 23 March 1999. CAT has been informed that MorphoSys AG, a German company, has filed a complaint in the US District Court for the District of Columbia seeking a declaration that MorphoSys is not infringing the above patent and that the patent is invalid. The complaint does not set out a factual basis as to why MorphoSys believes it is not infringing this patent or why the patent should be declared invalid. CAT has been advised that there is no sound basis in US Law for this complaint. In September 1998, as previously announced, CAT initiated a patent infringement action against MorphosSys in the District Court in Munich Germany for infringement of two other patents granted in Europe claiming different subject matter. These patents, Winter II and McCafferty et al, were granted in April 1994 and November 1996 respectively. A hearing in respect of this action is expected later this year. Neither this US complaint nor the action in Germany in any way impacts on CAT's freedom to operate its technology. CAT is committed to enforcing its patents where necessary. END MSCIRMRBLLTTMAL
1 Year Catco Reinsurance Opport... Chart |
1 Month Catco Reinsurance Opport... Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions